Minchong Kim

Dr. Minchong Kim

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
MPMin Hui Park
Min Hui Park
JCJung Eun Choi
Jung Eun Choi
SKSu Hwan Kang
Su Hwan Kang
YBYoung Kyung Bae
Young Kyung Bae
Kim MC, et al. J Breast Cancer. 2022 Jun;25:e31. https://doi.org/10.4048/jbc.2022.25.e31

1 January 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
SKSun Young Kwon
Sun Young Kwon
JCJung Eun Choi
Jung Eun Choi
SKSu Hwan Kang
Su Hwan Kang
YBYoung Kyung Bae
Young Kyung Bae
Kim MC, et al. J Breast Cancer. 2023 Apr;26:e19. https://doi.org/10.4048/jbc.2023.26.e19

15 October 2024 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
ECEun Yoon Cho
Eun Yoon Cho
SPSo Yeon Park
So Yeon Park
HLHee Jin Lee
Hee Jin Lee
JLJi Shin Lee
Ji Shin Lee
YBYoung Kyung Bae
Young Kyung Bae
Purpose Notable effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer (BC) has focused pathologists’ attention. We studied the incidence and clinicopathologic characteristics of HER2-low BC, and the effects of immunohistochemistry (IHC) associated factors on HER2 IHC results.Materials and Methods The Breast Pathology Study Group of the Korean Society of Pathologists conducted a nationwide study using real-world data on HER2 status generated between January 2022 and December 2022. Information on HER2 IHC protocols at each participating institution was also collected.Results Total 11,416 patients from 25 institutions included in this study. Of these patients, 40.7% (range, 6.0% to 76.3%) were classified as HER2-zero, 41.7% (range, 10.5% to 69.1%) as HER2-low, and 17.5% (range, 6.7% to 34.0%) as HER2-positive. HER2-low tumors were associated with positive estrogen receptor and progesterone receptor statuses (p < 0.001 and p < 0.001, respectively). Antigen retrieval times (≥ 36 minutes vs. < 36 minutes) and antibody incubation times (≥ 12 minutes vs. < 12 minutes) affected on the frequency of HER2 IHC 1+ BC at institutions using the PATHWAY HER2 (4B5) IHC assay and BenchMark XT or Ultra staining instruments. Furthermore, discordant results between core needle biopsy and subsequent resection specimen HER2 statuses were observed in 24.1% (787/3,259) of the patients.Conclusion The overall incidence of HER2-low BC in South Korea concurs with those reported in previously published studies. Significant inter-institutional differences in HER2 IHC protocols were observed, and it may have impact on HER2-low status. Thus, we recommend standardizing HER2 IHC conditions to ensure precise patient selection for targeted therapy.

1 January 2020 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
SKSu Hwan Kang
Su Hwan Kang
JCJung Eun Choi
Jung Eun Choi
YBYoung Kyung Bae
Young Kyung Bae
Kim MC, et al. J Breast Cancer. 2019 Nov;23:e53. https://doi.org/10.4048/jbc.2020.23.e53

31 October 2023 in Journal of Yeungnam Medical Science
Verified
Journal Article
Open access
PDF file
MKMinchong Kim
Minchong Kim
MGMiJin Gu
MiJin Gu

15 March 2026 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
MKMinchong Kim
Minchong Kim
ECEun Yoon Cho
Eun Yoon Cho
HLHee Jin Lee
Hee Jin Lee
Ji Shin LeeJi Shin Lee
Ji Shin Lee
JKJee Yeon Kim
Jee Yeon Kim
YBYoung Kyung Bae
Young Kyung Bae
Background: This study aimed to determine the prevalence of human epidermal growth factor receptor 2 (HER2)–ultralow breast cancer among cases initially classified as HER2 immunohistochemistry (IHC) 0 and assess interobserver variability in interpreting low-level HER2 expression. Methods: In this multicenter retrospective study, all invasive breast cancer cases diagnosed between January and December 2022 across 10 Korean institutions were retrieved. Institutional pathologists reexamined HER2 IHC slides originally reported as IHC 0 according to the 2018 American Society of Clinical Oncology/College of American Pathologists guidelines and reclassified them as HER2-null (0), HER2-ultralow (0+), or HER2-low (1+). Slides from 10% of HER2-null and HER2-ultralow cases were digitized for central review and independently assessed by two pathologists, with discrepancies resolved by consensus. Results: Among 8,026 cases, 2,836 cases (35.5%) were initially reported as IHC 0. Upon re-review, 1,673 (59.0%), 1,139 (40.2%), and 24 (0.8%) cases were reclassified as HER2-null, HER2-ultralow, and HER2-low, respectively. The prevalence of HER2-ultralow breast cancer varied considerably across institutions (23.7%–78.1%). Central review of 268 digitized cases showed concordance in 193 cases (72.0%). Among the 75 discordant cases, 54 tumors (72.0%) were upgraded from HER2-null to HER2-ultralow, and 18 (24.0%) tumors were upgraded from HER2-ultralow to HER2-low. Furthermore, two tumors (2.7%) were downgraded from HER2-ultralow to HER2-null. Conclusions: Approximately 40% of cases initially categorized as IHC 0 were reclassified as HER2-ultralow. The substantial inter-institutional variability observed in interpreting low-level HER2 expression highlights the need for standardized training and quality assurance to ensure accurate identification of patients eligible for HER2-targeted antibody–drug conjugates.